Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsRespiratory

ICU · Respiratory

Acute respiratory distress syndrome: phenotyping and personalised ventilation

Also known as ARDS phenotypes · Personalised ventilation · Hyperinflammatory vs hypoinflammatory ARDS · Recruitment manoeuvres · Driving pressure · ARDS subphenotypes · Latent class analysis ARDS · Precision medicine ARDS · Focal vs non-focal ARDS · Direct vs indirect lung injury · Recruitable lung

ARDS is not a single disease — two distinct phenotypes have been identified. Hyperinflammatory ARDS (high inflammatory markers, vasopressor-dependent, lower mortality with higher PEEP): responds better to higher PEEP and prone positioning. Hypoinflammatory ARDS (lower inflammatory markers, more extrapulmonary cause): may not benefit from aggressive PEEP. Personalised ventilation: individualise PEEP based on recruitability (PEEP titration by P-V curves, EIT, oesophageal pressure), driving pressure (<15 cmH2O — Amato meta-analysis: driving pressure is the strongest predictor of mortality), and lung morphology (focal vs non-focal on CT — focal ARDS tolerates higher PEEP poorly). Recruitment manoeuvres controversial (ART trial: caused harm). Prone positioning beneficial for moderate-severe ARDS (PaO2/FiO2 <150). Latent class analysis of the ALVEOLI and FACTT trials (Calfee 2014) identified the hyperinflammatory (type 2) and hypoinflammatory (type 1) subphenotypes using biomarkers — IL-6, IL-8, soluble TNF receptor-1, angiopoietin-2, bicarbonate, protein C. The subphenotype determines treatment response: higher PEEP and simvastatin benefit the hyperinflammatory phenotype but may harm the hypoinflammatory phenotype (HARP-2 secondary analysis, Calfee 2018). Precision medicine in ARDS is evolving but not yet routine bedside practice.

high20 referencesUpdated 26 July 202621 min readVerification in progress

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Driving pressure >15 cmH2O is the strongest ventilator-related predictor of mortality
  • Recruitment manoeuvres can cause harm (ART trial: increased mortality) — use cautiously
  • Focal ARDS (consolidation in dependent lung only) does NOT tolerate high PEEP — worsens overdistension of healthy lung
  • Two ARDS phenotypes (hyper/hypoinflammatory) respond differently to PEEP, prone, and fluids
  • Higher PEEP benefits the hyperinflammatory subphenotype but may INCREASE mortality in the hypoinflammatory subphenotype
  • Simvastatin reduced mortality in the hyperinflammatory HARP-2 subphenotype but showed a harm signal in the hypoinflammatory subphenotype
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Driving pressure >15 cmH2O is the strongest ventilator-related predictor of mortality
  • Recruitment manoeuvres can cause harm (ART trial: increased mortality) — use cautiously
  • Focal ARDS (consolidation in dependent lung only) does NOT tolerate high PEEP — worsens overdistension of healthy lung
  • Two ARDS phenotypes (hyper/hypoinflammatory) respond differently to PEEP, prone, and fluids
  • Higher PEEP benefits the hyperinflammatory subphenotype but may INCREASE mortality in the hypoinflammatory subphenotype
  • Simvastatin reduced mortality in the hyperinflammatory HARP-2 subphenotype but showed a harm signal in the hypoinflammatory subphenotype

Overview & definition

The Berlin definition (Ranieri, JAMA 2012) classifies ARDS by timing (within one week of a known clinical insult), bilateral opacities not fully explained by effusions, lobar collapse, or nodules, origin of oedema not fully explained by cardiac failure or fluid overload, and hypoxaemia stratified into mild, moderate, and severe by the PaO₂/FiO₂ ratio under standard ventilator settings.[9] The definition deliberately lumps together a heterogeneous group of precipitants — pneumonia, aspiration, sepsis, trauma, pancreatitis, transfusion — under one umbrella. That heterogeneity is the central problem in ARDS: dozens of pharmacological trials (statins, beta-agonists, nitric oxide, keratinocyte growth factor, antioxidants, surfactants, stem cells) have been neutral overall despite sound preclinical rationale. The patients are not the same patient twice.

Phenotyping is the attempt to split that Berlin umbrella into biologically coherent subgroups that differ in prognosis AND in treatment response, so that ventilation, fluid strategy and drugs can be matched to the patient in front of you. Three overlapping phenotyping axes are in active use today: (1) biological subphenotypes identified by latent class analysis (hyper- versus hypoinflammatory); (2) radiographic / morphological phenotypes (focal versus non-focal, recruitable versus non-recruitable); and (3) aetiological phenotypes (direct versus indirect lung injury).[1][16][17]

In one line

ARDS phenotypes: hyperinflammatory (type 2 — high IL-6/sTNFr-1/angiopoietin-2, vasopressor-dependent, lower PaO2/FiO2, higher mortality, responds to higher PEEP, conservative fluids, and possibly simvastatin) vs hypoinflammatory (type 1 — low inflammation, better oxygenation, lower mortality, may be harmed by aggressive PEEP). Driving pressure (<15 cmH2O — strongest mortality predictor, Amato NEJM 2015). Focal vs non-focal ARDS on CT: focal does not tolerate high PEEP (overdistension). Recruitment manoeuvres: controversial (ART trial 2017: harm). Prone positioning: for PaO2/FiO2 <150 (PROSEVA: reduces mortality). Personalise: VT 6 mL/kg, driving pressure <15, PEEP titrated to recruitability, prone if moderate-severe.

[1]
ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References20ShowHide
  1. [1]Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials Lancet Respir Med, 2014.PMID 24853585
  2. [2]Amato MBP, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome N Engl J Med, 2015.PMID 25693014
  3. [3]Famous KR, Delucchi K, Ware LB, et al. Acute Respiratory Distress Syndrome Subphenotypes Respond Differently to Randomized Fluid Management Strategy Am J Respir Crit Care Med, 2017.PMID 27513822
  4. [4]Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial Lancet Respir Med, 2018.PMID 30078618
  5. [5]Sinha P, Delucchi KL, Thompson BT, et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study Intensive Care Med, 2018.PMID 30291376
  6. [6]Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS; ARDS Network. Stability of ARDS subphenotypes over time in two randomised controlled trials Thorax, 2018.PMID 29477989
  7. [7]McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome N Engl J Med, 2014.PMID 25268516
  8. [8]Truwit JD, Bernard GR, Steingrub J, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome N Engl J Med, 2014.PMID 24835849
  9. [9]Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition JAMA, 2012.PMID 22797452
  10. [10]Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome N Engl J Med, 2013.PMID 23688302
  11. [11]Cavalcanti AB, Suzumura ÉA, Laranjeira LN, et al. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial JAMA, 2017.PMID 28973363
  12. [12]Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury N Engl J Med, 2006.PMID 16714767
  13. [13]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome N Engl J Med, 2010.PMID 20843245
  14. [14]Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome N Engl J Med, 2019.PMID 31112383
  15. [15]Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome N Engl J Med, 2018.PMID 29791822
  16. [16]Gattinoni L, Caironi P, Cressoni M, et al. Lung recruitment in patients with the acute respiratory distress syndrome N Engl J Med, 2006.PMID 16641394
  17. [17]Pelosi P, D'Onofrio D, Chiumello D, et al. Pulmonary and extrapulmonary acute respiratory distress syndrome are different Eur Respir J Suppl, 2003.PMID 12946001
  18. [18]Moore AR, Pienkos SM, Sinha P, et al. Elevated Plasma Interleukin-18 Identifies High-Risk Acute Respiratory Distress Syndrome Patients not Distinguished by Prior Latent Class Analyses Using Traditional Inflammatory Cytokines: A Retrospective Analysis of Two Randomized Clinical Trials Crit Care Med, 2023.PMID 37695136
  19. [19]Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study Lancet Respir Med, 2020.PMID 32861275
  20. [20]Guérin C, Papazian L, Reignier J, et al. Effect of driving pressure on mortality in ARDS patients during lung protective mechanical ventilation in two randomized controlled trials Crit Care, 2016.PMID 27894328

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAcute Respiratory Distress Syndrome (ARDS) — Berlin Definition, Lung-Protective Ventilation, Proning, ECMO, and PhenotypingrespiratoryNextAcute respiratory distress syndrome: phenotyping and precision medicineRespiratory